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ABSTRACT
Objectives: Although cognitive behaviour therapy
(CBT) and pharmacotherapy are equally effective in the
acute treatment of adult depression, it is not known
how they compare across the longer term. In this
meta-analysis, we compared the effects of acute phase
CBT without any subsequent treatment with the effects
of pharmacotherapy that either were continued or
discontinued across 6–18 months of follow-up.
Design: We conducted systematic searches in
bibliographical databases to identify relevant studies,
and conducted a meta-analysis of studies meeting
inclusion criteria.
Setting: Mental healthcare.
Participants: Patients with depressive disorders.
Interventions: CBT and pharmacotherapy for
depression.
Outcome measures: Relapse rates at long-term
follow-up.
Results: 9 studies with 506 patients were included.
The quality was relatively high. Short-term outcomes
of CBT and pharmacotherapy were comparable,
although drop out from treatment was significantly
lower in CBT. Acute phase CBT was compared with
pharmacotherapy discontinuation during follow-up in
eight studies. Patients who received acute phase CBT
were significantly less likely to relapse than patients
who were withdrawn from pharmacotherapy
(OR=2.61, 95% CI 1.58 to 4.31, p<0.001; numbers-
needed-to-be-treated, NNT=5). The acute phase CBT
was compared with continued pharmacotherapy at
follow-up in five studies. There was no significant
difference between acute phase CBT and continued
pharmacotherapy, although there was a trend (p<0.1)
indicating that patients who received acute phase
CBT may be less likely to relapse following acute
treatment termination than patients who were
continued on pharmacotherapy (OR=1.62, 95% CI
0.97 to 2.72; NNT=10).
Conclusions: We found that CBT has an enduring effect
following termination of the acute treatment. We found no
significant difference in relapse after the acute phase CBT
versus continuation of pharmacotherapy after remission.
Given the small number of studies, this finding should be
interpreted with caution pending replication.
INTRODUCTION
It is well established that cognitive behaviour
therapy (CBT) is efﬁcacious in the treatment
of adult depression. Dozens of randomised
trials have shown that CBT is superior to no
treatment, non-speciﬁc controls or
care-as-usual in the acute treatment of adult
depression,1 2 and that the effects of CBT are
comparable to those of antidepressant phar-
macotherapies, albeit with lower rates of attri-
tion for CBT.3
What is not clear, however, is how acute
CBT compares with pharmacotherapy over
the longer term. It has long been claimed
that psychotherapy leads to lasting change
because patients learn skills that can be
implemented after the treatment has ended
and because they are instructed on speciﬁc
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techniques on how to handle relapse. CBT has been
found to have an enduring effect that lasts beyond the
end of treatment.4 No such claim has ever been made
for pharmacotherapy.5 Nonetheless, it is well established
that keeping patients on pharmacotherapy even after
they are better can reduce the risk of subsequent
symptom return, and it is standard practice to keep
patients with chronic or recurrent depressions on
pharmacotherapy indeﬁnitely.6
If CBT has an enduring effect that extends beyond
the end of treatment, it is important to know how that
compares with simply keeping patients on pharmaco-
therapy. This is important from a clinical point of view,
since clinicians and patients have to decide which
modality to choose at the outset of treatment and will
want to consider information about the relative long-
term effects of each in their initial decision.
Improvement during acute treatment is called response
and the full normalisation of symptoms is called remis-
sion.7 Recently remitted patients typically are kept on
continuation pharmacotherapy for another 6–12 months in
order to reduce the risk of relapse, the return of symp-
toms associated with the treated episode, and patients
who have gone that long without relapse are said to be
recovered, with the presumption that the underlying
episode has run its course. Keeping recovered patients
on maintenance pharmacotherapy beyond that point is
intended to reduce the risk for recurrence, the onset of a
wholly new episode, and is standard for chronic or recur-
rent patients.7
Although several studies have compared the long-term
effects of acute CBT with those of continuation pharma-
cotherapy, no meta-analysis of these studies has been
conducted. One earlier review examined whether the
acute phase CBT had an enduring effect relative to
medication withdrawal, but no direct comparison was
made against continuation pharmacotherapy.8 Since the
continued prescription of pharmacotherapy is now the
current standard of treatment and the key decision that
clinicians need to make, we decided to conduct such a
meta-analysis.
In this meta-analysis, we focus on two research ques-
tions. The ﬁrst question is whether acute phase CBT
without continuation treatment is as effective as acute
phase pharmacotherapy treatment with continuation
treatment. The second question is whether acute phase
CBT without continuation treatment is as effective as
acute phase pharmacotherapy treatment without con-
tinuation treatment.
METHODS
Identification and selection of studies
We used a database of 1344 papers on the psychological
treatment of depression described in detail elsewhere9
that has been used to conduct a series of published
meta-analyses (http://www.evidencebasedpsychotherapies.
org). This database is continuously updated through
comprehensive literature searches (from 1966 to January
2012). In these searches, we examined 13 407 abstracts in
PubMed (3320 abstracts), PsycInfo (2710), EMBASE
(4389) and the Cochrane Central Register of Controlled
Trials (2988). These abstracts were identiﬁed by combining
terms indicative of psychological treatment and depression
(both MeSH terms and text words). We also checked the
references from 42 meta-analyses of psychological treat-
ment for depression to ensure that no published studies
were missed. From the 13 407 abstracts (9860 after removal
of duplicates), 1344 full-text papers were retrieved for pos-
sible database inclusion.
We included (a) randomised trials (b) in which the
effects of CBT (c) according to the manual by Beck et al10
(c) were compared with the effects of pharmacological
treatment (d) in adults (e) with a diagnosed depressive
disorder, (f) across a follow-up period of 6–18 months.
We focused on studies that compared acute CBT
(without subsequent continuation) versus pharmacother-
apy that was either continued or withdrawn, and con-
ducted separate comparisons on each.
Studies in which CBT was continued during follow-up
were excluded, although we allowed a maximum of ﬁve
booster sessions during follow-up, as long as these were
not regularly planned. We set the limit at ﬁve booster
sessions because most of the psychological treatments
have six or more treatment sessions.11 We also excluded
studies in which depression was not diagnosed with a
standardised diagnostic interview (such as Composite
International Diagnostic Interview, Structured Clinical
Interview for DSM Disorders or Mini-International
Neuropsychiatric Interview), as well as studies in inpati-
ents and adolescents. No language restrictions were
applied.
Quality assessment and data extraction
The validity of included studies was assessed on four cri-
teria of the ‘risk of bias’ assessment tool developed by
the Cochrane Collaboration to assess the possible
sources of bias in randomised trials: (1) adequate gener-
ation of allocation sequence, (2) concealment of alloca-
tion to conditions, (3) prevention of knowledge of the
allocated intervention (blinding) and (4) dealing with
incomplete outcome data.12 The two other criteria of
the ‘risk of bias’ assessment tool were not used in this
study, because we found no clear indication in any of
the studies that these had inﬂuenced the validity of the
study (suggestions of selective outcome reporting and
other problems that could put it at a high risk of bias).
We collected characteristics of the target population
(method of recruitment, deﬁnition of depression),
HAMD score (Hamilton Depression Rating Scale) at the
start of the treatment to assess the severity of depression,
whether all randomised patients were examined at
follow-up or only responders to acute phase treatment,
the number of treatment sessions, type of drug, whether
pharmacotherapy was continued across the full follow-up
or only for part of that period, and the country where
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the study was conducted. If all information was not
reported in the paper, we contacted the authors of the
papers requesting additional information (all six of
whom responded).
Meta-analyses
For each study, we used the number of patients who
responded to treatment and remained well as outcome
measures (the exact deﬁnition of the outcome in each
study was reported in table 1, column ‘outcome’). We
calculated the OR of a positive outcome in CBT com-
pared with pharmacotherapy. We calculated these ORs
at the end of the acute treatment (response or remis-
sion) and across the subsequent follow-up (freedom
from relapse or recurrence). Although at least some of
the follow-ups were long enough for patients free from
relapse to have met the criteria for recovery (and subse-
quent episodes of recurrences); we will use the term
relapse to refer to all instances of symptom return.
To calculate the pooled ORs, we used the computer
program Comprehensive Meta-Analysis (V.2.2.021). We
calculated the pooled ORs with the ﬁxed effects model
as well as with the random effects model. The calcula-
tions were conducted according to the procedures given
by Borenstein et al.13 Because the results of these ana-
lyses being almost identical, we only report the results of
the random effects model.
The numbers-needed-to-be-treated (NNT) is intuitively
easier to understand than OR. NNT indicates the
number of patients that would have to be treated in
order to generate one additional positive outcome.14
Therefore, we also calculated NNT for all comparisons.
We calculated the risk differences (RDs) for each study,
pooled these for all the studies, and then calculated the
NNT as 1/RD for the pooled studies.
As a test of homogeneity of effect sizes, we calculated
the I2 statistic, an indicator of heterogeneity in percen-
tages. A value of 0% indicates no observed heterogen-
eity, and larger values show increasing heterogeneity,
with 25% as low, 50% as moderate, and 75% as high het-
erogeneity.15 We calculated 95% CIs around I2,16 using
the non-central χ2-based approach within the heterogi
module for Stata.17
Subgroup analyses between different subsamples of
studies were conducted according to the mixed effects
model. In this model, studies within subgroups are
pooled with the random effects model, while tests for
signiﬁcant differences between subgroups are conducted
with the ﬁxed effects model.
Publication bias was tested by inspecting funnel plots
on the primary outcome measures and by Duval and
Tweedie’s18 trim and ﬁll procedure, which yields an esti-
mate of the effect size after adjusting for publication
bias (as implemented in Comprehensive Meta-Analysis,
V.2.2.021). We conducted Egger’s test of the intercept as
well as Begg and Mazumdar’s test to quantify the bias
captured by the funnel plot and test whether it was sig-
niﬁcant.19 We also calculated Orwin’s fail-safe N, which
indicates the number of missing studies needed to make
the effect size insigniﬁcant.20
RESULTS
Selection and inclusion of studies
After examining a total of 13 407 abstracts (9860 after
removal of duplicates), we retrieved 1344 full text papers
for further consideration. We excluded 1335 of the
retrieved papers. The ﬂow chart describing the inclusion
process, including the reasons for exclusion, is presented
in ﬁgure 1. In total, 9 of the 1344 retrieved full-text
papers reported long-term outcomes of the acute phase
CBT and were included in this meta-analysis.21–29
Characteristics of the included studies
In the nine included studies, a total of 506 patients parti-
cipated, 271 in CBT and 235 in pharmacotherapy. The
selected characteristics of the included studies are pre-
sented in table 1.
Four studies recruited patients only from clinical
samples, while the other ﬁve also recruited patients
from the community. Six studies included only patients
who responded to acute phase treatment in the analyses
of the subsequent follow-ups, while the other three
included all patients randomised to acute phase treat-
ment. The number of CBT treatment sessions ranged
from 18 to 24. During the follow-up phase (after acute
treatment had ended), three studies offered up to four
CBT booster sessions, while the other six did not offer
any additional treatment.
In ﬁve earlier studies, a tricyclic antidepressant (TCA)
was used in the pharmacotherapy condition, while the
three more recent studies all used a selective serotonin
reuptake inhibitor (SSRI); in one study, phenelzine
(a monoamine oxidase inhibitor) was used. In four
studies, patients who responded to pharmacotherapy
were randomised to either continuation pharmacother-
apy (for the ﬁrst year of the 2-year follow-up) or
pharmacotherapy withdrawal with each reported separ-
ately. In three other trials, all the patients were with-
drawn from pharmacotherapy, although the length of
the taper differed across the trials. One other trial con-
tinued pharmacotherapy for the ﬁrst 6 months follow-up
before subsequent withdrawal, and in the remaining
trial, pharmacotherapy was continued throughout the
follow-up. In most instances, patients withdrawn from
treatment were followed naturalistically, although in
several studies they were encouraged not to seek add-
itional treatment until a relapse or recurrence was docu-
mented. Seven studies were conducted in the USA, two
in Europe (one in the UK and one in Romania).
Quality of included studies
Eight of the nine studies used an adequate sequence
generation strategy and had an independent party
conceal allocations to conditions. Six studies reported
keeping the assessors blind to treatment condition and
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Table 1 The selected characteristics of the studies comparing the long-term effects of CBT for adult depression with those of pharmacotherapy
Recr DD Pre-HAMD Included*
Psychotherapy Pharmacotherapy
FU Outcome C
Quality
Acute
phase Nsess
Continuation
phase N
Acute
phase
Continuation
phase N SG AC BA CF
Blackburn et al21 Clin MDD (PSE/RDC) NR Resp CBT 23 4 Boosters (in
the first
6 months)
13 Drug of
choice
Continuation of
6 months,
remaining period
naturalistic
9 24 Depressive
symptoms
needing further
treatment
UK − − − −
David, et al22 Com
+clin
MDD (DSM-IV)
+BDI≥20+HAMD
17≥14
22.1 All CBT 20 Maximum
three booster
sessions
56 Fluoxetine Continued
pharmacotherapy
57 6 No current MDD
+HAMD≤7
RO + + + +
Dobson, et al23 Com
+clin
MDD (DSM-IV)
+BDI-II≥20
+HAMD 17≥14
20.7 Resp CBT 24 No treatment
offered during
FU
30 Paroxetine Continued
pharmacotherapy
28 12 Sustained
response (no
2 weeks
HAMD≥14)
USA + + + +
Evans, et al24 Clin MDD (RDC) 26.9 Resp CBT 20 No continued
treatment
10 Imipramine Continued
pharmacotherapy
during 1 year,
then tapered
11 24 No relapse
(BDI≥16 during
at least 2 weeks)
+no treatment
USA + + + +
Hollon, et al25 Com/
clin
MDD (DSM-IV) 23.4 Resp CBT 20 Up to three
booster
sessions
60 Paroxetine Continued
pharmacotherapy
34 12 No relapse (no
HAMD≥14 for
two consecutive
weeks)
USA + + + +
Jarret, et al26 Com/
clin
Atypical MDD
(DSM-IV; SCID)
18.4 Resp CBT 20 No continued
treatment
6 Phenelzine Continued
pharmacotherapy
6 24 Relapse/
recurrence
according to
RDC
USA + + + +
Kovacs, et al27 Com/
clin
DD (Feigh-ner)
+HAMD 17≥14
+BDI≥20
21.5 Resp CBT 20 Naturalistic 18 Imipramine Naturalistic 17 12 All monthly BDI
scores during
FU≤16
USA + + − −
Shea, et al28 Clin MDD (RDC)
+HAMD≥14
19.6 All CBT 18 Naturalistic 59 Imipramine Pharmacotherapy
was gradually
reduced
57 18 Recovered
(LIFE-II) and no
relapse (MDD/
RDC)
USA + + + +
Simons, et al29 Clin DD (DIS)
+HAMD≥14 or
BDI≥20
19.9 Resp CBT 20 No additional
treatment
19 Nortriptyline Pharmacotherapy
was gradually
tapered
16 12 Did not re-enter
treatment+no
BDI≥16 at FU
USA + + − +
*Only responders to the acute phase treatments or the ones who completed the acute phase treatment were included in the FU analyses.
AC, allocation concealment; All, all randomised patients; BA, blind assessment; BDI, Beck Depression Inventory; C, country; CBT, cognitive behaviour therapy; CF, completeness of FU data;
clin, clinical recruitment; com, community recruitment; DD, depressive disorder; DIS, diagnostic interview schedule; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth
edition; FU, follow-up; HAMD, Hamilton Depression Rating Scale; LIFE-II, longitudinal interval FU evaluation; MDD, major depressive disorder; Nsess, number of sessions; NR, not reported;
PSE, present state examination; RDC, research diagnostic criteria; Recr, recruitment; Resp, only responders to the acute phase; RO, Romania; SG, sequence generation; SCID, Structured
Clinical Interview for DSM Disorders.
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seven studies conducted intent-to-treat analyses. The six
studies published in the last two decades met all four of
the quality criteria; among the three earlier studies, one
study met three, another met two, and yet another met
none of the criteria (table 1). The overall quality of the
studies was relatively high, compared with the quality of
the studies on psychotherapy for adult depression in
general.30
Long-term outcomes: acute phase CBT versus continuation
pharmacotherapy
Five studies compared the 1-year outcomes of acute
phase CBT (with nothing more than occasional booster
sessions) versus continuation pharmacotherapy.22–26
There was a trend (p<0.1) indicating that the acute
phase CBT outperformed continuation pharmacother-
apy (OR=1.62, 95% CI 0.97 to 2.72). Heterogeneity was
zero, but the 95% CI was broad (0% to 79%), so this
ﬁnding should be interpreted with caution. NNT was 10.
ORs and 95% CIs are presented graphically in ﬁgure 2.
After exclusion of a possible outlier, OR was signiﬁcant
(OR=1.77, 95% CI 1.04 to 3.01; NNT=8). As can be
seen, however, the pooled ORs are heavily reliant on just
two studies, although most of the studies pointed in the
same direction. The results should therefore be consid-
ered with caution.
We found no indication of publication bias (not sur-
prising given the dearth of studies). Using Duval and
Tweedie’s trim and ﬁll procedure to adjust for
publication bias did not change OR (the number of
trimmed studies was zero). Egger’s test and Begg and
Mazumbar’s test were not signiﬁcant (p>0.1). We also
calculated Orwin’s fail-safe N and found that 23 studies
with an OR of 0.9 or eleven studies with an OR of 0.8
(in favour of pharmacotherapy) or 7 studies with an OR
of 0.7 would be needed to produce a pooled OR of
1.00. No additional subgroup analyses were conducted
because of the small number of studies.
Long-term outcomes: acute phase CBT versus
pharmacotherapy discontinuation
Eight studies compared the 1-year outcomes of acute
phase CBT (with nothing more than occasional booster
Figure 1 Flow chart of inclusion
of studies.
Figure 2 Long-term effects of cognitive behaviour therapy
(without continuation during follow-up) compared with
pharmacotherapy (continued during follow-up): Forest plot of
OR of response.
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sessions) versus pharmacotherapy discontinuation or a
naturalistic design. The acute phase CBT signiﬁcantly
outperformed the pharmacotherapy discontinuation
condition to an even greater extent than it had continu-
ation pharmacotherapy (OR=2.61, 95% CI 1.58 to 4.31;
p<0.001). Heterogeneity was zero, but again the 95% CI
was broad (0% to 68%). The corresponding NNT was 5
(95% CI 4 to 11). ORs and 95% CI for each study are
presented graphically in ﬁgure 3.
Because two studies had a very high OR21 24 and one
had a very low OR,26 we conducted an additional sensi-
tivity analysis with these studies removed. The resulting
OR was somewhat smaller (OR=2.47, 95% CI 1.45 to
4.22), though still highly signiﬁcant (p<0.001), and the
corresponding NNT was 6 (95% CI 4 to 15). Again,
these results were heavily reliant on just two studies, and
the results should be considered with caution.
Although the number of studies was small, we did
conduct some subgroup analyses. We did not ﬁnd any
signiﬁcant differences between subgroups, including
medication type (SSRI vs TCA), whether all randomised
patients were included versus inclusion of responders to
the acute phase only, and studies with the highest
quality (meeting all 4 criteria) versus those with lower
quality (≤3 criteria). These outcomes should be inter-
preted with caution, however, because of the small
sample sizes in the subgroups.
Short-term outcomes
We also examined the comparative effects of CBT versus
pharmacotherapy in the short term (end of acute treat-
ment), but found no signiﬁcant difference (OR=1.15, n.s.;
table 2). Excluding one potential outlier27 did not affect
this ﬁnding.
We also examined whether we could conﬁrm that the
drop out from the intervention was signiﬁcantly higher
in pharmacotherapy than in CBT, as has been estab-
lished in earlier meta-analyses.3 Eight of the nine studies
reported sufﬁcient data on drop out to be included in
the analyses. We found that the odds of dropping out in
the acute phase were signiﬁcantly lower in CBT than in
pharmacotherapy (OR=0.59, 95% CI 0.34 to 0.99).
Inspection of the funnel plot indicated that several
studies could have been outliers. Because of the small
number of studies, however, we did not conduct any add-
itional sensitivity analyses.
DISCUSSION
We found that patients treated acutely with CBT were
less likely to relapse following acute treatment termin-
ation than patients treated acutely with pharmacother-
apy. We did not ﬁnd that patients treated with acute
phase CBT had a signiﬁcantly lower risk of relapse than
patients on pharmacotherapy. There was a non-
signiﬁcant trend (p<0.1) suggesting that relapse rates
may be lower after acute phase CBT, but there were too
few studies on the long-term effects of CBT and continu-
ation pharmacotherapy to draw deﬁnite conclusions.
More research is needed before this question can be
resolved.
It has been found in earlier research that patients are
as likely to respond to CBT as to pharmacotherapy and
are less likely to drop out of treatment.3 Moreover, there
are indications that the majority of patients who respond
to pharmacotherapy do so for non-speciﬁc reasons; that
is, they show a placebo response and not a ‘true’ drug
effect. The same appears to be true for the psychosocial
treatments including CBT.31 The fact that CBT results in
lower relapse rates than discontinued pharmacotherapy
not only suggests that CBT has a speciﬁc enduring effect
that may operate through somewhat different mechan-
isms than its acute effects, but also conﬁrms its strong
position as a ﬁrst-line treatment of acute depressive
disorders.
The results of this meta-analysis should be interpreted
with caution because of a number of limitations. The
most important limitation was that small number of
studies comparing CBT with continued pharmacother-
apy. Also, the number of patients in these studies was
relatively small, and the results of the main analyses
relied heavily on just a few studies. In such a situation,
only a few additional studies with different outcomes can
turn these results from a trend to non-signiﬁcance.
Another possible limitation is that there was consider-
able variation in the methods used between the studies
in terms of pharmacotherapy, measures and other char-
acteristics. Also, some studies only included responders
to the acute phase in the follow-up analyses, which may
have led to bias in the overall results. If high risk patients
were more likely to respond to pharmacotherapy than to
CBT, then acute treatment could have acted as a ‘differ-
ential sieve’ that systematically unbalanced the groups
and led to the differential retention of patients differing
in an a priori risk being misinterpreted as an enduring
effect. Another possible limitation is that the follow-up
of the CBT conditions in most of the studies was natural-
istic, although some asked patients not to pursue outside
Figure 3 Long-term effects of cognitive behaviour therapy
(without continuation during follow-up) compared with
pharmacotherapy (discontinued during follow-up): Forest plot
of OR of response.
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treatment in the absence of a documented relapse and
censored those events on the few times that they did
occur. However, there were important differences
between the studies in terms of treatment received
during the follow-up phase. There also was considerable
variability in when pharmacotherapy was discontinued
across the studies, although that should only have led us
to underestimate the ‘true’ magnitude of the advantage
for acute phase CBT in that comparison. Moreover, the
quality of the studies included in this meta-analysis was
high, and even if the next ten studies all produced an
advantage for ongoing continued pharmacotherapy,
acute phase CBT would still be as efﬁcacious as continu-
ation pharmacotherapy. Subsequent replication is
needed before a possible superiority of acute phase CBT
over continuation pharmacotherapy can be taken ser-
iously, but the possibility is of sufﬁcient importance that
such efforts clearly should be made.
Studies on the long-term effects of treatments of
depression are complicated, because subsequent
treatment is difﬁcult to control (but not impossible to
inﬂuence). Another complication is that patients both
need to complete and respond to acute treatment in
order to be at risk for subsequent relapse or recurrence;
large numbers of patients need to be randomised ini-
tially to differential treatment in order to have enough
patients remit to detect anything but the largest subse-
quent differences during follow-up. Furthermore, acute
and continuation/maintenance treatments can be
offered in several varieties and the latter can be changed
during the course of the follow-up. The number of pos-
sible comparisons is therefore large, but all are needed
to give an adequate answer to the question which treat-
ment is the best for the longer term. The most import-
ant design for a future study, however, would be a
sufﬁciently powered trial comparing acute phase CBT
without subsequent continuation versus acute phase
pharmacotherapy with subsequent continuation (the
current standard of treatment). Although some studies
have used this design, none had sufﬁcient statistical
Table 2 Long-term effects of CBT compared with pharmacotherapy: ORs of response†
N OR 95% CI I2‡ 95% CI NNT 95% CI p§
CBT vs continued pharmacotherapy
All studies 5 1.62 0.97 to 2.72 * 0 0 to 79 10 ¶
One possible outlier excluded†† 4 1.77 1.04 to 3.01 0 0 to 85 8 4 to 71
CBT vs discontinued pharmacotherapy
All studies 8 2.61 1.58 to 4.31**** 0 0 to 68 5 4 to 11
Three possible outliers excluded‡‡ 5 2.47 1.45 to 4.22**** 0 0 to 79 6 4 to 15
Subgroups (long-term effects)
Pharmacotherapy§§
SSRI 2 3.02 1.29 to 7.04** 0 ¶¶ 5 0.82
TCA 5 2.66 1.40 to 5.04*** 0 0 to 79 6 4 to 15
Included sample
All 2 1.97 0.91 to 4.27 * 0 ¶¶ 9 ¶ 0.14
Responders 6 3.20 1.65 to 6.19*** 0 0 to 75 4 3 to 8
Quality
All 4 criteria 5 2.31 1.28 to 4.16*** 0 0 to 79 6 2 to 11 0.25
≤3 criteria 3 3.58 1.39 to 9.22*** 0 0 to 90 4 2 to 10
Short-term effects
All the studies 9 1.15 0.74 to 1.79 53 0 to 78 20 ¶
One possible outlier excluded††† 8 0.96 0.72 to 1.30 0 0 to 68 ¶
Drop out from intervention‡‡‡ 8 0.59 0.34 to 0.99** 48 0 to 77 9 5 to 143
*p<0.1.
**p<0.05.
***p<0.01.
****p<0.001.
†According to the random effects model.
‡In this column, I2 is reported; we also tested whether the Q value was significant. This was the case in two comparisons (indicated with an
asterisk*).
§The p value indicates whether the subgroups differ from each other.
¶The 95% CI includes zero and would result in a negative NNT; therefore, we do not report the 95% of the NNT here the 95% CI included
zero; because this would result in a negative NNT, we do not report this here.
††Jarrett et al26.
‡‡Blackburn et al, 1981; Jarrett et al26; Evans et al24.
§§One study examined phenelzine ( Jarrett et al26); this was not included in the analyses.
¶¶95% CI could not be calculated when degrees of freedom is lower than two.
†††Kovacs et al27.
‡‡‡One study did not report data on drop out (Blackburn et al 21).
CBT, cognitive behaviour therapy; NNT, numbers-needed-to-be-treated; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic
antidepressant.
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power to ﬁnd signiﬁcant differences of the magnitude
(modest but clinically relevant) between the two sug-
gested by this meta-analysis. It seems highly relevant to
conduct such a trial.
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